ORMP
Oramed Pharmaceuticals Inc.3.0800
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
122.73MP/E (TTM)
3.08Basic EPS (TTM)
1.00Dividend Yield
0%Recent Filings
8-K
Oramed sells Oratech, buys Lifeward notes
Oramed closed the sale of its subsidiary Oratech to Lifeward on March 25, 2026, receiving 1,250,363 Lifeward ordinary shares, 1,006,113 pre-funded warrants, and warrants for 1,296,296 shares at $5.40, plus 4% revenue sharing on ReWalk exoskeletons until $200M market cap or 10 years. Simultaneously, Oramed bought $9M senior secured convertible notes from Lifeward at $5.40 conversion and warrants for 1,666,666 shares. Deal swaps assets for equity exposure.
10-K
FY2025 results
Oramed swung to $64M net income for FY2025 ended December 31, 2025, fueled by $89M financial gains from revaluing Scilex notes and Alpha Tau shares, yet operations lost $15M on $2M HTIT licensing revenue after IIA repayment costs. Q4 momentum shone through $28.5M warrant sales and $9.9M Scilex repayments, trimming notes while Alpha Tau stake doubled to 17% ($72M fair value). Buybacks retired 2.1M shares for $4.7M; $46M cash remains ample. $0.25/share dividend declared. Scilex default risk looms large.
8-K
Oramed gets Scilex warrant
Oramed deferred a Scilex amortization payment due October 1, 2025 under its Tranche B Note—paid in November—in exchange for an immediately exercisable warrant for 100,000 Scilex shares at $20.00, expiring December 13, 2029, with a $8.22 floor. Ownership capped at 4.99%, adjustable to 9.99%. Scilex must register resale by March 31, 2026. Sweetens note exposure.
8-K
Oramed sells oral insulin unit to Lifeward
Oramed Pharmaceuticals entered a Share Purchase Agreement on January 12, 2026, to sell its subsidiary Oratech—housing the POD oral insulin platform—to Lifeward for up to 49.99% of Lifeward's equity, warrants tied to Lifeward's net cash at $0.45/share, and 4% net revenue share on ReWalk exoskeletons until $40M cap, 10 years, or $200M market cap. Concurrently, Oramed leads a $9M tranche of Lifeward's $10M senior secured convertible notes at 8% interest, convertible at $0.45/share, with a milestone $9M additional tranche; closings hinge on Lifeward shareholder approval. Oramed retains clinical trial management of the insulin study. Shareholder votes pending.
8-K
Oramed gets $18M, approves dividend
Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings on January 7, 2026, fully settling Option Agreement obligations and boosting total returns to $118 million on its $99.5 million investment. The board approved a $0.25 per share dividend, totaling ~$10.5 million, payable January 26 to record holders on January 16, funded by surplus capital. Oramed retains $39 million in notes, warrants, and royalties. Returns keep flowing.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
OCEA
Ocean Biomediacal, Inc.
0.00+0.00
OGEN
Oragenics Inc.
0.83-0.01
OMER
Omeros Corporation
8.77-0.43
ORGS
Orgenesis, Inc.
0.15-0.01
ORIC
Oric Pharmaceuticals, Inc.
9.12-0.11
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
OVID
Ovid Therapeutics Inc.
1.55-0.01
TELO
Telomir Pharmaceuticals, Inc.
1.40-0.02